Table 2.
Seroconversion rates based on neutralizing antibody titers.
| Seroconversion | AZD1222 | MVC-COV1901 | Treatment Difference1, % | p-value2 |
|---|---|---|---|---|
| Seropositive in PPI subset | ||||
| n | 70 | 72 | 0.03 | |
| Seroconversion, n(%) | 63 (90) | 71 (98.6) | 8.6 | |
| 95 % CI | 82.97–97.03 | 95.9–100 | 1.1–16.1 | |
| Seronegative in PPI subset | ||||
| n | 39 | 44 | 0.218 | |
| Seroconversion, n(%) | 37 (94.9) | 44 (100.0) | 5.1 | |
| 95 % CI | 82.7–99.4 | 91.95–100 | −1.8–12 | |
Abbreviation: n = no. of participants, CI = confidence interval, GMT = geometric mean titer, GMFR = geometric mean fold rise, PPI = per-protocol immunogenicity.
Note: Seroconversion was defined as at least 4-fold increase of post-study intervention antibody titers from the baseline titer or from half of the lower limit of detection if undetectable at baseline.
[1] Treatment Difference was computed as, MVC-COV1901-AZD1222 and presented with the asymptotic 95 % CI. In the case of small cell count (expected count <5), exact 95 % CI was applied alternatively.
[2] P-value: Pearson's Chi-square test. In the case of small cell count (expected count <5), Fisher's exact test was applied alternatively.